HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2
HER-2 overexpression	Solid Tumor	HER-2 overexpression	Solid Tumor	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2
EGFR mutation	Solid Tumor	EGFR mutation	Solid Tumor	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2
HER-2 positive	Cholangiocarcinoma	HER-2 positive	Cholangiocarcinoma	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3
HER-2 positive	Esophageal Cancer	HER-2 positive	Esophageal Cancer	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3
HER-2 rearrangement	Solid Tumor	HER-2 rearrangement	Solid Tumor	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER2 exon 20 mutation inhibitor Sensitive: C3 – Early Trials HER2 exon 20 mutation inhibitor Sensitive : C3	HER2 exon 20 mutation inhibitor Sensitive: C3 – Early Trials HER2 exon 20 mutation inhibitor Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	BAY 2927088 Sensitive: C3 – Early Trials BAY 2927088 Sensitive : C3	BAY 2927088 Sensitive: C3 – Early Trials BAY 2927088 Sensitive : C3
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	ORIC-114 Sensitive: C3 – Early Trials ORIC-114 Sensitive : C3	ORIC-114 Sensitive: C3 – Early Trials ORIC-114 Sensitive : C3
HER-2 mutation	Esophageal Cancer	HER-2 mutation	Esophageal Cancer	BI 1810631 Sensitive: C4 – Case Studies BI 1810631 Sensitive : C4	BI 1810631 Sensitive: C4 – Case Studies BI 1810631 Sensitive : C4
HER-2 mutation	Cholangiocarcinoma	HER-2 mutation	Cholangiocarcinoma	BI 1810631 Sensitive: C4 – Case Studies BI 1810631 Sensitive : C4	BI 1810631 Sensitive: C4 – Case Studies BI 1810631 Sensitive : C4
EGFR H773_V774insH	Non Small Cell Lung Cancer	EGFR H773_V774insH	Non Small Cell Lung Cancer	ORIC-114 Sensitive: D – Preclinical ORIC-114 Sensitive : D	ORIC-114 Sensitive: D – Preclinical ORIC-114 Sensitive : D
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	TY-4028 Sensitive: D – Preclinical TY-4028 Sensitive : D	TY-4028 Sensitive: D – Preclinical TY-4028 Sensitive : D
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	TY-4028 Sensitive: D – Preclinical TY-4028 Sensitive : D	TY-4028 Sensitive: D – Preclinical TY-4028 Sensitive : D

HER2 exon 20 mutation inhibitor

HER2 exon 20 mutation inhibitor

Associations(18)

Associations
(18)